EA202190342A1 - Гетеробициклические соединения для ингибирования активности shp2 - Google Patents

Гетеробициклические соединения для ингибирования активности shp2

Info

Publication number
EA202190342A1
EA202190342A1 EA202190342A EA202190342A EA202190342A1 EA 202190342 A1 EA202190342 A1 EA 202190342A1 EA 202190342 A EA202190342 A EA 202190342A EA 202190342 A EA202190342 A EA 202190342A EA 202190342 A1 EA202190342 A1 EA 202190342A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterobicyclic compounds
shp2 activity
inhibiting shp2
inhibiting
heterobicyclic
Prior art date
Application number
EA202190342A
Other languages
English (en)
Inventor
Тадаси СИМАМУРА
Рё Като
Рисако Миура
Такаси Мита
Такахиро ОГАВА
Юфу Сагара
Кристофер Норберт Джонсон
Стивен Говард
Джеймс Эдвард Харви Дэй
Джеффри Дэвид Сен Дени
Джон Уолтер Либешютц
Original Assignee
Тайхо Фармасьютикал Ко., Лтд.
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайхо Фармасьютикал Ко., Лтд., Оцука Фармасьютикал Ко., Лтд. filed Critical Тайхо Фармасьютикал Ко., Лтд.
Publication of EA202190342A1 publication Critical patent/EA202190342A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединение формулы (I)где кольцо A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c и d имеют значение, определенное в описании.
EA202190342A 2018-07-24 2019-07-23 Гетеробициклические соединения для ингибирования активности shp2 EA202190342A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018138244 2018-07-24
PCT/JP2019/028822 WO2020022323A1 (en) 2018-07-24 2019-07-23 Heterobicyclic compounds for inhibiting the activity of shp2

Publications (1)

Publication Number Publication Date
EA202190342A1 true EA202190342A1 (ru) 2021-07-22

Family

ID=69180650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190342A EA202190342A1 (ru) 2018-07-24 2019-07-23 Гетеробициклические соединения для ингибирования активности shp2

Country Status (17)

Country Link
US (1) US20220363693A1 (ru)
EP (1) EP3827009A4 (ru)
JP (1) JP7174143B2 (ru)
KR (1) KR102579709B1 (ru)
CN (1) CN112513050A (ru)
AU (1) AU2019309987B2 (ru)
BR (1) BR112021001292A2 (ru)
CA (1) CA3107411C (ru)
EA (1) EA202190342A1 (ru)
IL (1) IL280331B2 (ru)
MA (1) MA53395A (ru)
MX (1) MX2021000795A (ru)
PH (1) PH12021550167A1 (ru)
SA (1) SA521421089B1 (ru)
SG (1) SG11202100719YA (ru)
TW (1) TW202019921A (ru)
WO (1) WO2020022323A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
CN109475531B (zh) 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Ptpn11的杂环抑制剂
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2
EP3759111A1 (en) 2018-03-02 2021-01-06 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compounds
MX2020009782A (es) 2018-03-21 2021-01-20 Relay Therapeutics Inc Inhibidores de la fosfatasa shp2 y métodos para su uso.
MX2020011528A (es) 2018-05-02 2021-02-09 Navire Pharma Inc Inhibidores heterociclicos sustituidos de ptpn11.
EP4356973A3 (en) 2018-08-10 2024-06-26 Navire Pharma, Inc. 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
US20200115389A1 (en) 2018-09-18 2020-04-16 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
MX2022003454A (es) 2019-09-24 2022-04-19 Relay Therapeutics Inc Inhibidores de fosfatasa shp2 y metodos para su fabricacion y uso.
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co Ltd IMPROVEMENT OF THE ANTITUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS IN CANCER
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
JP7373664B2 (ja) 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
US20230322812A1 (en) 2020-08-24 2023-10-12 Taiho Pharmaceutical Co., Ltd. Crystalline form of heterobicyclic compound
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
EP4039685A1 (en) * 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
CN113717178B (zh) * 2021-09-30 2022-07-22 上海皓鸿生物医药科技有限公司 一种shp2抑制剂的中间体及其制备方法
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023168036A1 (en) 2022-03-04 2023-09-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023221721A1 (zh) * 2022-05-20 2023-11-23 安徽中科拓苒药物科学研究有限公司 Shp2抑制剂及其用途
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN116589410B (zh) * 2023-05-29 2024-05-03 济南国鼎医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6361562B2 (ja) 2015-04-17 2018-07-25 株式会社デンソー モータ制御装置、及び、電動パワーステアリング装置
US10975080B2 (en) * 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
BR112017027951A2 (pt) * 2015-06-22 2018-08-28 Ono Pharmaceutical Co., Ltd. composto inibitório de brk
WO2017156397A1 (en) * 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
CN109475531B (zh) * 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Ptpn11的杂环抑制剂
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW201819386A (zh) 2016-10-24 2018-06-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
ES2964956T3 (es) * 2017-01-10 2024-04-10 Novartis Ag Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2
TW201927791A (zh) * 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
US20200392161A1 (en) * 2018-02-21 2020-12-17 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
EP3759111A1 (en) 2018-03-02 2021-01-06 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2019309987A1 (en) 2021-03-11
EP3827009A1 (en) 2021-06-02
BR112021001292A2 (pt) 2021-05-11
IL280331B1 (en) 2023-08-01
CA3107411A1 (en) 2020-01-30
IL280331A (en) 2021-03-25
TW202019921A (zh) 2020-06-01
SG11202100719YA (en) 2021-02-25
KR102579709B1 (ko) 2023-09-15
CN112513050A (zh) 2021-03-16
JP2021531296A (ja) 2021-11-18
MA53395A (fr) 2021-06-02
MX2021000795A (es) 2021-04-12
WO2020022323A1 (en) 2020-01-30
JP7174143B2 (ja) 2022-11-17
EP3827009A4 (en) 2022-04-27
PH12021550167A1 (en) 2021-09-13
KR20210040399A (ko) 2021-04-13
AU2019309987B2 (en) 2022-08-18
US20220363693A1 (en) 2022-11-17
IL280331B2 (en) 2023-12-01
CA3107411C (en) 2023-09-26
SA521421089B1 (ar) 2023-01-22

Similar Documents

Publication Publication Date Title
EA202190342A1 (ru) Гетеробициклические соединения для ингибирования активности shp2
NZ732649A (en) Picolinamides and related compounds
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA202190657A1 (ru) Ингибиторы саркомера сердца
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
EA202092921A1 (ru) Полициклическое производное карбамоилпиридона
AR115949A1 (es) Compuestos heterocíclicos
NZ732810A (en) Picolinamides and other compounds
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA202092923A1 (ru) Полициклическое производное пиридона
EA201171004A1 (ru) Пиридазиноновые соединения
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
MY169179A (en) Novel piperidine compound or salt thereof
EA202190462A1 (ru) Индольные и азаиндольные ингибиторы ферментов pad
MX2016015467A (es) Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
AR114309A1 (es) Compuestos antibacterianos, composiciones de los mismos, y métodos que utilizan los mismos
MY195201A (en) Biaryl Derivative and Medicine Containing Same
EA201692190A1 (ru) Соединения фосфина золота (i) в качестве антибактериальных агентов
PH12020552185A1 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
ZA202101487B (en) Novel compounds
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
EA202090653A1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
EA202090933A1 (ru) Способ получения гербицидных соединений пиридазинона